Board of Directors

Iain has over 40 years' experience in the international life sciences and technology sectors and has held significant roles in multi-national companies including Sandoz, Hoffman La Roche, and Celltech Group plc. He has completed multiple financing transactions and turnarounds and has over 30 years' experience in cross-border management as a chairman and CEO. He has led and participated in eight Initial Public Offerings (IPOs) and has direct experience of M&A transactions in Europe, the USA and the Pacific Rim. Iain led the turnaround and re-structuring of several biotech companies including Ark Therapeutics, Redx Pharma, Silence Therapeutics and more recently, ReNeuron.

Alexandre was born in Ukraine, grew up in Georgia, and later studied mathematics, physics, chemistry, biochemistry, and biophysics at the Moscow Institute of Physics and Technology, all countries then being part of the USSR. In 1989, he was selected by the George Soros Foundation for the Oxford Scholarship, associated with St. Antony’s College, along with 20 top Soviet graduate students. He obtained his PhD in cell biology from University College, London (with the research-based at the Imperial Cancer Research Fund). He then spent six years at the Robert Wood Johnson Medical School-UMDNJ, NJ, as a research assistant funded by the Howard Hughes Medical Institute. Upon his return to England, he established his research laboratory at the Sir William Dunn School of Pathology, University of Oxford. He was a University Academic Fellow (Research Council UK) and a Senior Fellow of Exeter College, sponsored by Cancer Research UK, the Wellcome Trust, and The Medical Research Council. Alexandre is a Fellow of the Royal Society of Medicine.

Paul joined the Company in September 2017 from e-Therapeutics plc, where he held the position of Financial Controller from 2012. Paul is a Chartered Accountant and was a Senior Manager at Deloitte, where he worked from 1996 until 2004. Following this, he worked in finance and operations management in the charitable and automotive sectors. He read Natural Sciences at St John's College, University of Cambridge.

Stephen is the founder and Chief Executive Officer of Vulpes Investment Management, and co-founder and former managing partner of Artradis Fund Management, one of the largest hedge fund groups in Asia. Stephen has been involved in equity capital markets for nearly 30 years, leading trading teams across a number of institutions including Salomon Brothers and Lehman Brothers, and has considerable experience investing in and supporting life science businesses through the Vulpes Life Sciences Fund. Stephen holds an MA from the University of Oxford.

David is a proven leader in business development and healthcare investing, with 30 years’ experience in the life sciences sector. A qualified physician and MBA graduate from Harvard Business School, he has worked for a variety of companies, charities and academic institutions including: GlaxoSmithKline, Roche, Imperial College London and the University of Cambridge. In addition to his non-executive directorship at OBD, David is also a non-executive director of AIM-listed Frontier IP plc, a non-executive director of MitoRx Limited, a mitochondrial biology company based at Harwell, holds roles as Adviser and Investment Committee member at RYSE Asset Management, is Chairman of The Liver Group Charity, and recently appointed Chair of NK:IO Limited, a private spin out company of Imperial College. David brings a wealth of healthcare investment expertise as inaugural Head of Seed Funds at LifeArc, General Partner and Head of Healthcare Investing at MTI Ventures LLP, Director, Life Sciences at the Cambridge University Seed Fund and July 2021, Senior Independent Director at Worldwide Healthcare Trust plc. David was appointed to the OBD Board in April 2019. He chairs the Remuneration Committee and is a member of the Audit and Nomination Committees.

Peter Presland is an experienced Non-Executive Director and Chairman with 50 years' experience in business, much of that at the highest levels of management within both public and private companies. A law graduate at King's College, University of London, he qualified as a Chartered Accountant with Arthur Andersen. In 1980, he joined C E Heath plc ("Heath"), a major publicly quoted international insurance group, as Group Accountant/Treasurer and became in 1985 the Group Finance Director. He was promoted to Heath's Group Chief Executive in 1990, and in 1996 led the demerger of Heath's computer services operations into a separate publicly listed company, Rebus Group plc, becoming its Chief Executive and in 1999 its Chairman. Since 2001, Peter has pursued a portfolio non-executive career, becoming Chairman of a number of IT and financial services companies, including LINK, the UK ATM network, in 2003 where he led a major corporate governance change as well as the merger of LINK with Voca, the provider of the BACS service, becoming Chairman of VocaLink in 2007. Among other appointments, from 2012 to 2015, he served as Chairman of the Audit & Governance Committee of East Kent Hospitals NHS Trust, in 2017 was appointed to the board of Redx Pharma PLC, and in 2019 was asked to become Chairman of the Governance & Finance Committee of the Lord's Taverners, a high-profile charity.

Peter joined the Board in March 2025. He chairs the Audit Committee and sits on the Remuneration and Nomination committees.